EUVIMEDEUVIMED entdecken
LeserbriefOpen Access

A High-Throughput Screening Platform Identifies FDA-Approved Drugs That Inhibit SREBP Pathway Activation

Chiaki T Ishida iD, Casie S Kubota iD, Evan Carlyle, Takashi Tsukamoto iD, Peter J Espenshade

ACS Chemical Biology · 2024

DOI: 10.1021/acschembio.4c00354 ↗

Kurz gefasst

Leserbrief in der Zeitschrift ACS Chemical Biology, 2024. Verfasst von Chiaki T Ishida und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, Johns Hopkins University, Baltimore, Maryland 21205 United States. Hauptthemen laut MEDLINE: High-Throughput Screening Assays, Sterol Regulatory Element Binding Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

High-Throughput Screening AssaysSterol Regulatory Element Binding ProteinsHumansCell Line, TumorSignal TransductionUnited StatesSmall Molecule LibrariesDrug ApprovalCell ProliferationUnited States Food and Drug AdministrationAntineoplastic Agents

Substanzen

Sterol Regulatory Element Binding ProteinsSmall Molecule LibrariesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Cell Biology, Johns Hopkins University, Baltimore, Maryland 21205 United States.
  • Johns Hopkins Drug Discovery and Department of Neurology, Johns Hopkins University, Baltimore, Maryland 21205 United States.
  • Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University,Baltimore, Maryland 21205 United States.
  • Giovanis Institute for Translational Cell Biology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 United States.

ORCID-Profile: Chiaki T Ishida, Casie S Kubota, Takashi Tsukamoto

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • National Cancer Institute
  • Division of Graduate Education
  • National Institute of General Medical Sciences

Zitieren

APA

T Ishida, C., Kubota, C. S., Carlyle, E., Tsukamoto, T., & Espenshade, P. J. (2024). A High-Throughput Screening Platform Identifies FDA-Approved Drugs That Inhibit SREBP Pathway Activation. ACS Chemical Biology. https://doi.org/10.1021/acschembio.4c00354

Vancouver

T Ishida C, Kubota CS, Carlyle E, Tsukamoto T, Espenshade PJ. A High-Throughput Screening Platform Identifies FDA-Approved Drugs That Inhibit SREBP Pathway Activation. ACS Chemical Biology. 2024. doi:10.1021/acschembio.4c00354

BibTeX
@article{TIshida2024,
  author = {T Ishida, Chiaki and Kubota, Casie S and Carlyle, Evan and Tsukamoto, Takashi and Espenshade, Peter J},
  title = {A High-Throughput Screening Platform Identifies FDA-Approved Drugs That Inhibit SREBP Pathway Activation},
  journal = {ACS Chemical Biology},
  year = {2024},
  doi = {10.1021/acschembio.4c00354}
}
Kostenlos starten →